Company Filing History:
7 out of 7,278 
1 out of 5,194 
1 out of 5 Years Active: 2004-2020
Title: Christopher J Patten: Innovator in Drug Screening Technologies
Introduction:
Christopher J Patten, a resident of Scituate, MA, is a respected inventor with a strong presence in the field of drug screening technologies. With nine patents to his name, Patten's innovative contributions have significantly impacted the pharmaceutical industry. This article delves into his latest patents, career highlights, collaborations, and highlights his valuable contributions to the field.
Latest Patents:
Patten's latest patents revolve around cryopreserved recombinant cells for screening drug candidates. The invention involves cells that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. By providing a cost-efficient consumable product, this advancement streamlines the intricate process of determining whether drug candidates are substrates or inhibitors of specific drug transporter proteins or drug metabolizing enzymes. Patten's patents showcase his expertise in adapting cell-based assays for more efficient and effective drug screening methodologies.
Career Highlights:
Throughout his career, Patten has worked with prominent companies, making remarkable contributions to the field of pharmaceuticals. Notably, he has been associated with Corning Incorporated, a leader in materials science, and Becton Dickinson and Company Limited, an influential medical technology manufacturing company. These experiences have allowed Patten to gain valuable insights and collaborate with top professionals in the industry.
Collaborations:
Collaboration plays a crucial role in innovation, and Patten has had the opportunity to work alongside talented individuals to bring his ideas to fruition. Na Li and Jie Wang are two of his notable coworkers, who have likely contributed to the success of his patented inventions. Such collaborations exemplify Patten's ability to form productive partnerships to develop cutting-edge technologies, ultimately resulting in advancements within the drug screening field.
Conclusion:
Christopher J Patten's dedication and expertise in drug screening technologies have culminated in an impressive collection of patents. His cutting-edge inventions, involving cryopreserved recombinant cells, have paved the way for more efficient drug screening processes. Through his contributions, Patten has made substantial strides in streamlining drug discovery methods, benefiting the pharmaceutical industry as a whole. His career highlights and collaborations further emphasize his impressive insights and commitment to innovation. As the field continues to evolve, we eagerly anticipate the next breakthroughs that Christopher J Patten will bring to the world of drug screening technologies.